Global Custom Market Research Reports Provider Company

phone

Primary Sclerosing Cholangitis - Pipeline Review, H2 2018

  • Published Date: 10 Jul 2018
  • Number of Pages: 111
  • Category: Pharmaceuticals
  • Country: Global
Primary Sclerosing Cholangitis - Pipeline Review, H2 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Primary Sclerosing Cholangitis - Pipeline Review, H2 2018, provides an overview of the Primary Sclerosing Cholangitis (Gastrointestinal) pipeline landscape.

Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by a progressive course of cholestasis with inflammation and fibrosis of the intrahepatic and extra hepatic bile ducts. Symptoms include abdominal pain, chills, diarrhea, fatigue, itchiness and weight loss. The predisposing factors include age and inflammatory bowel diseases. Treatment includes antibiotics and bile-acid-binding drugs.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Primary Sclerosing Cholangitis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Primary Sclerosing Cholangitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Primary Sclerosing Cholangitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Sclerosing Cholangitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 10, 1, 6 and 1 respectively.

Primary Sclerosing Cholangitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Sclerosing Cholangitis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Primary Sclerosing Cholangitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Primary Sclerosing Cholangitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Primary Sclerosing Cholangitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Primary Sclerosing Cholangitis (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Primary Sclerosing Cholangitis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Primary Sclerosing Cholangitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Publisher Name : Global Markets Direct

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Primary Sclerosing Cholangitis - Overview
Primary Sclerosing Cholangitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Primary Sclerosing Cholangitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Primary Sclerosing Cholangitis - Companies Involved in Therapeutics Development
Acorda Therapeutics Inc
Albireo Pharma Inc
Allergan Plc
Conatus Pharmaceuticals Inc
Dr. Falk Pharma GmbH
DURECT Corp
Gilead Sciences Inc
Intercept Pharmaceuticals Inc
NGM Biopharmaceuticals Inc
Noxopharm Ltd
Sancilio & Company Inc
Seres Therapeutics Inc
Shenzhen HighTide Biopharmaceutical Ltd
Shire Plc
Sirnaomics Inc
Primary Sclerosing Cholangitis - Drug Profiles
A-4250 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
berberine ursodeoxycholate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologics for Liver Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cenicriviroc - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CM-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DUR-928 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GS-9674 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HTD-1801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IDN-7314 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
maralixibat chloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NGM-282 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
norursodeoxycholic acid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NYX-205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
obeticholic acid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SC-404 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SC-435 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Autoimmune Hepatitis and Primary Sclerosing Cholangitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STP-705 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
timolumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Primary Sclerosing Cholangitis - Dormant Projects
Primary Sclerosing Cholangitis - Discontinued Products
Primary Sclerosing Cholangitis - Product Development Milestones
Featured News & Press Releases
Apr 19, 2018: Albireo to Present Data from Two Studies on Cholestatic Liver Disease at the 51st ESPGHAN Annual Meeting
Apr 18, 2018: Conatus Pharmaceuticals IDN-7314 Pan-caspase Inhibitor Reduces Hepatic Tissue Factor-Driven Coagulation In Vitro and In Vivo
Apr 13, 2018: NGM Bio Announces Late-Breaking Plenary Presentation At International Liver Conference 2018 Of Detailed Results From Phase 2 Study Of NGM282 In Patients With Primary Sclerosing Cholangitis
Apr 09, 2018: Conatus Pharmaceuticals Announces Upcoming Oral Presentation at EASL Annual Meeting
Feb 26, 2018: DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Primary Sclerosing Cholangitis
Feb 20, 2018: DURECT to Host Key Opinion Leader Call on Treatment of Primary Sclerosing Cholangitis (PSC)
Feb 05, 2018: NGM Reports Top-Line Results From Phase 2 Study Of NGM282 In Patients With Primary Sclerosing Cholangitis (PSC)
Nov 01, 2017: Intercept Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update
Oct 23, 2017: Intercept Announces Positive Results from Phase 2 AESOP Trial Evaluating OCA for the Treatment of Patients with Primary Sclerosing Cholangitis at The Liver Meeting 2017
Oct 20, 2017: Conatus Pharmaceuticals Announces Poster Presentation at AASLD Annual Meeting
Oct 18, 2017: EMA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSC
Oct 11, 2017: Intercept Announces Data to be Presented at The Liver Meeting 2017
Sep 25, 2017: Intercept Statement Regarding Ocaliva (obeticholic acid) Safety and Dosing in Primary Biliary Cholangitis Patients
Aug 01, 2017: Sirnaomics Leading siRNA Therapeutic Candidate, STP705, Granted Orphan Designation for the Treatment of Primary Sclerosing Cholangitis
Jul 31, 2017: Intercept Announces Positive Results from the Phase 2 AESOP Trial Evaluating OCA for the Treatment of Patients with Primary Sclerosing Cholangitis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

List of Tables
Number of Products under Development for Primary Sclerosing Cholangitis, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Primary Sclerosing Cholangitis - Pipeline by Acorda Therapeutics Inc, H2 2018
Primary Sclerosing Cholangitis - Pipeline by Albireo Pharma Inc, H2 2018
Primary Sclerosing Cholangitis - Pipeline by Allergan Plc, H2 2018
Primary Sclerosing Cholangitis - Pipeline by Conatus Pharmaceuticals Inc, H2 2018
Primary Sclerosing Cholangitis - Pipeline by Dr. Falk Pharma GmbH, H2 2018
Primary Sclerosing Cholangitis - Pipeline by DURECT Corp, H2 2018
Primary Sclerosing Cholangitis - Pipeline by Gilead Sciences Inc, H2 2018
Primary Sclerosing Cholangitis - Pipeline by Intercept Pharmaceuticals Inc, H2 2018
Primary Sclerosing Cholangitis - Pipeline by NGM Biopharmaceuticals Inc, H2 2018
Primary Sclerosing Cholangitis - Pipeline by Noxopharm Ltd, H2 2018
Primary Sclerosing Cholangitis - Pipeline by Sancilio & Company Inc, H2 2018
Primary Sclerosing Cholangitis - Pipeline by Seres Therapeutics Inc, H2 2018
Primary Sclerosing Cholangitis - Pipeline by Shenzhen HighTide Biopharmaceutical Ltd, H2 2018
Primary Sclerosing Cholangitis - Pipeline by Shire Plc, H2 2018
Primary Sclerosing Cholangitis - Pipeline by Sirnaomics Inc, H2 2018
Primary Sclerosing Cholangitis - Dormant Projects, H2 2018
Primary Sclerosing Cholangitis - Discontinued Products, H2 2018

List Of Figures

List of Figures
Number of Products under Development for Primary Sclerosing Cholangitis, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Pipeline Review, H2 2018 According to the recently published report Transmembrane Prolyl 4 Hydroxylase -

View Report

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H2 2018 CD40 Ligand (T

View Report

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Pipeline Review, H2 2018 Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports